List of Tuxarin Er drug patents
Tuxarin Er is owned by Mainpointe.
Tuxarin Er contains Chlorpheniramine Maleate; Codeine Phosphate.
Tuxarin Er has a total of 2 drug patents out of which 0 drug patents have expired.
Tuxarin Er was authorised for market use on 22 June, 2015.
Tuxarin Er is available in tablet, extended release;oral dosage forms.
Tuxarin Er can be used as treatment of cough and symptoms associated with upper respiratory allergies or a common cold with codeine phosphate and chlorpheniramine maleate orally administered extended release tablets.
The generics of Tuxarin Er are possible to be released after 03 January, 2032.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9066942 | MAINPOINTE | Oral dosage forms for oxygen-containing active agents and oxyl-containing polymer |
Jan, 2032
(8 years from now) | |
| US9107921 | MAINPOINTE | Oral dosage forms for oxygen containing active agents and oxyl-containing polymers |
Jan, 2032
(8 years from now) | |
Drugs and Companies using CHLORPHENIRAMINE MALEATE; CODEINE PHOSPHATE ingredient
Market Authorisation Date: 22 June, 2015
Treatment: Treatment of cough and symptoms associated with upper respiratory allergies or a common cold with codeine phosphate and chlorpheniramine maleate orally administered extended release tablets
Dosage: TABLET, EXTENDED RELEASE;ORAL
TUXARIN ER family patents
8
United States
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic